Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
about
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?5-α reductase inhibitors and prostate cancer prevention: where do we turn now?A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancerEffects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.Prostate field cancerization: deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissueEarly growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization.Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer preventionFinasteride and prostate cancer: a commentaryOverview of methods in economic analyses of behavioral interventions to promote oral healthDoes variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?The burden of prostate cancer in Canada.Finasteride in the treatment of patients with benign prostatic hyperplasia: a reviewFinasteride.Prevention strategies in prostate cancer.Chemoprevention of prostate cancer: an updated view.Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges.Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy.
P2860
Q33710942-4BD4704C-A139-40C2-8E8A-3137C13E0C7BQ34020127-9DBED48F-5E8A-4A71-A671-FB71352A58FCQ34141355-0FA56367-DC35-4646-A678-F34B57F90636Q34511194-80DF2894-0B1C-42B0-8F45-494136F0FEB7Q34689090-B7D5B310-7E2B-4DB7-8939-2FBE846728BBQ35175108-8A36E9E2-930B-49FC-A152-4CAD060A53C4Q35923141-9A34E412-8020-4A78-B2FA-2685044A625BQ36080332-E7F74EC5-7488-425A-9D81-6B637BC83751Q36102792-6F05A53D-C393-4A2B-A116-8349AA02DEDEQ36745358-D68A4ACF-41B7-4668-811E-708DBBD8E28AQ36883768-44A79396-E075-43AF-9453-7E19B36F45D0Q37233474-AA535794-2D0B-470F-B7B9-623185091BA8Q37261063-A8727474-846F-4A4C-9C3C-5A3D4B0A64CEQ37763952-09C5DCF5-48F8-40AF-BFE3-46C62A41456AQ37794799-0BDAE7BA-16A9-4034-8A32-CE65843B5774Q37975188-A89CDB19-198C-4EC1-B24A-64E22367FA1EQ38092015-42F9E338-A054-4061-A0BF-AA483FE7BF2DQ42955159-6375D1E9-CBCF-4218-8BF2-2FB49B13E080
P2860
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@en
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@nl
type
label
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@en
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@nl
prefLabel
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@en
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@nl
P2093
P356
P1433
P1476
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
@en
P2093
Claus G Roehrborn
J Jack Lee
Robert S Svatek
Scott M Lippman
P304
P356
10.1002/CNCR.23276
P407
P50
P577
2008-03-01T00:00:00Z